Massachusetts Financial Services Co. MA Has $377.54 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Massachusetts Financial Services Co. MA lessened its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,384,990 shares of the medical research company's stock after selling 97,828 shares during the quarter. Massachusetts Financial Services Co. MA owned 1.81% of Natera worth $377,544,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. increased its holdings in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after acquiring an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares during the last quarter. Principal Securities Inc. boosted its holdings in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its stake in Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Piper Sandler boosted their price objective on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. Robert W. Baird increased their price objective on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Sanford C. Bernstein increased their price objective on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a report on Friday, January 10th. The Goldman Sachs Group increased their price target on Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Finally, Guggenheim raised their target price on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research note on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $178.12.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 24,861 shares of the business's stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,101,319.17. Following the completion of the transaction, the insider now directly owns 140,684 shares of the company's stock, valued at approximately $23,208,639.48. The trade was a 15.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 25,931 shares of the company's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07. Following the transaction, the chief financial officer now directly owns 109,665 shares in the company, valued at approximately $18,091,435.05. This represents a 19.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 325,922 shares of company stock valued at $51,603,664 in the last ninety days. Insiders own 7.60% of the company's stock.

Natera Stock Performance

Shares of NTRA traded up $2.36 during trading hours on Monday, reaching $136.23. 794,991 shares of the company traded hands, compared to its average volume of 1,375,834. The stock's fifty day moving average is $156.81 and its 200 day moving average is $151.57. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a market cap of $18.42 billion, a P/E ratio of -77.03 and a beta of 1.80. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.